| 94698-8 | Epilepsy autoimmune Ab pnl SerPl | 21 |
| 94700-2 | Liver diseases autoimmune Ab pnl SerPl | 4 |
| 94701-0 | Movement autoimmune Ab pnl SerPl | 20 |
| 94707-7 | Dementia autoimmune Ab pnl CSF | 17 |
| 94708-5 | Encephalopathy autoimmune Ab pnl CSF | 19 |
| 94709-3 | Epilepsy autoimmune Ab pnl CSF | 18 |
| 94712-7 | Movement autoimmune Ab pnl CSF | 17 |
| 94818-2 | Paraneoplastic Ab Pnl CSF IF | 25 |
| 94848-9 | Functional assessment standardized items (FASI) - version 1.0:-:RptPeriod:^Patient:-:CMS Assessment | 3 |
| 94849-7 | FASI v1.0 - Self-care - usual performance:-:RptPeriod:^Patient:-:CMS Assessment | 24 |
| 94850-5 | FASI v1.0 - Self-care - most dependent performance:-:1Mo:^Patient:-:CMS Assessment | 24 |
| 94851-3 | FASI v1.0 - Mobility - usual performance:-:RptPeriod:^Patient:-:CMS Assessment | 60 |
| 94852-1 | FASI v1.0 - Mobility - most dependent performance:-:1Mo:^Patient:-:CMS Assessment | 57 |
| 94853-9 | WNV IgG+IgM Pnl CSF | 3 |
| 94854-7 | WNV IgG+IgM Pnl Ser | 3 |
| 94855-4 | carBAMazepine hypersens geno Pnl Bld/T | 4 |
| 94859-6 | Glycerol + glycerol corr TG Pnl SerPl | 6 |
| 94864-6 | TTR-assoc familial amyloidosis Pnl Bld | 5 |
| 94871-1 | Aldosterone + Na Pnl 24h Ur | 3 |
| 94872-9 | Chol + Trigl Pnl Fld | 4 |
| 94873-7 | Cortis F p corticotropin stim Pnl SerPl | 4 |
| 94911-5 | Living arrangement priorities for the next 6Mo:-:RptPeriod:^Patient:-:CMS Assessment | 6 |
| 95020-4 | FASI v1.0 - Self-care:-:-:^Patient:-:CMS Assessment | 9 |
| 95023-8 | FASI v1.0 - Mobility:-:-:^Patient:-:CMS Assessment | 6 |
| 95024-6 | FASI v1.0 - Manual wheelchair - usual performance:-:RptPeriod:^Patient:-:CMS Assessment | 12 |
| 95025-3 | FASI v1.0 - Manual wheelchair - most dependent performance:-:1Mo:^Patient:-:CMS Assessment | 12 |
| 95026-1 | FASI v1.0 - Motorized wheelchair &or scooter - most dependent performance:-:1Mo:^Patient:-:CMS Assessment | 12 |
| 95027-9 | FASI v1.0 - Motorized wheelchair &or scooter - usual performance:-:RptPeriod:^Patient:-:CMS Assessment | 12 |
| 95028-7 | FASI v1.0 - Instrumental Activities of Daily Living:-:-:^Patient:-:CMS Assessment | 9 |
| 95029-5 | FASI v1.0 - Instrumental Activities of Daily Living - usual performance:-:RptPeriod:^Patient:-:CMS Assessment | 36 |
| 95030-3 | FASI v1.0 - Instrumental Activities of Daily Living - most dependent performance:-:1Mo:^Patient:-:CMS Assessment | 36 |
| 95031-1 | FASI v1.0 - Assistive Devices for Everyday Activities:-:RptPeriod:^Patient:-:CMS Assessment | 99 |
| 95032-9 | FASI v1.0 - Functional Abilities and Goals:-:-:^Patient:-:CMS Assessment | 18 |
| 95033-7 | FASI v1.0 - Preferences for Customary Routine and Activities:-:-:^Patient:-:CMS Assessment | 17 |
| 95034-5 | FASI v1.0 - Availability of Assistance:-:RptPeriod:^Patient:-:CMS Assessment | 6 |
| 95035-2 | FASI v1.0 - Availability of Paid and Unpaid Assistance:-:RptPeriod:^Patient:-:CMS Assessment | 6 |
| 95036-0 | FASI v1.0 - Availability of Paid Assistance:-:RptPeriod:^Patient:-:CMS Assessment | 24 |
| 95037-8 | FASI v1.0 - Availability of Unpaid Assistance:-:RptPeriod:^Patient:-:CMS Assessment | 24 |
| 95056-8 | Catechols Sup Stand Pnl Plas | 7 |
| 95080-8 | C peptide p Cfst + meal Pnl SerPl | 15 |
| 95091-5 | Glucagon p Cfst + meal Pnl SerPl | 13 |
| 95102-0 | Glucose p Cfst + meal Pnl SerPl | 16 |
| 95110-3 | Insulin p Cfst + meal Pnl SerPl | 15 |
| 95121-0 | Fact VIII Act + Inhib Pnl PPP Chro | 5 |
| 95126-9 | Lipid & glucose Pnl SerPl | 9 |
| 95131-9 | FASI v1.0 - Mobility (Wheelchair):-:-:^Patient:-:CMS Assessment | 18 |
| 95136-8 | CMV DNA Pnl Amn NAA+probe | 4 |
| 95137-6 | B19V DNA Pnl Amn NAA+probe | 6 |
| 95138-4 | EBV DNA Pnl Amn NAA+probe | 6 |
| 95139-2 | VZV DNA Pnl Amn NAA+probe | 6 |